Recent Press Releases

Earnings and Business Update Scheduled for February 18th

DUBLIN, Jan. 12, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT), in advance of the start of the 33rd Annual J.P. Morgan Healthcare Conference, today announced that based on a preliminary review of 2014...

AbbVie Announces U.S. FDA Approval of DUOPA™ (carbidopa and levodopa) Enteral Suspension for the Treatment of Motor Fluctuations in Patients with Advanced Parkinson's Disease

DUOPA is the first and only treatment providing 16 continuous hours of carbidopa and levodopa for motor fluctuations in advanced Parkinson's disease · In a clinical trial, patients treated...

Merck Provides Update on Strategic Actions to Transform the Company and Build a Platform for Sustained Future Growth at the 33rd Annual J.P. Morgan Healthcare Conference

KEYTRUDA, First FDA-Approved Anti-PD-1 Therapy, Filed and Launched Within Five Months Company Expects to Submit sBLA for KEYTRUDA in Mid-Year 2015 for Advanced Non-Small Cell Lung Cancer NDA...

AMAG Pharmaceuticals Provides Business Update and 2015 Financial Guidance

Integration of Lumara Health acquisition substantially complete Estimated pro forma fourth quarter 2014 product sales of $74 million 2015 sales guidance of $355 million represents +300%...

Keryx Biopharmaceuticals Announces Transition of Leadership

The Role of Chief Executive Officer Transitioning From Ron Bentsur to Greg Madison NEW YORK and BOSTON, Jan. 11, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the...

Vertex Outlines 2015 Business Priorities to Support the Development, Approval and Launch of New Medicines for the Treatment of People with Cystic Fibrosis

Priority Review granted for combination of lumacaftor and ivacaftor in people with cystic fibrosis ages 12 and older who have two copies of the F508del mutation; PDUFA date of July 5, 2015 More...

CheckMate -017, A Phase 3 Study of Opdivo (Nivolumab) Compared to Docetaxel in Patients with Second-Line Squamous Cell Non-small Cell Lung Cancer, Stopped Early

Opdivo demonstrates superior overall survival in this Phase 3 trial (PRINCETON, NJ, January 11, 2015) – Bristol-Myers Squibb Company (NYSE:BMY) today announced that an open-label, randomized...

Shire to Acquire NPS Pharma as Further Step in Building a Leading Biotech

Shire to Acquire NPS Pharma as Further Step in Building a Leading Biotech Transaction valued at $5.2 billion Enhances growth profile Dublin, Ireland and Bedminster, NJ – January 11, 2015...

Record number of medicines for rare diseases recommended for approval in 2014

Number of medicines with new active substances continues to increase In 2014, the European Medicines Agency (EMA) recommended the highest number of orphan designated medicines for marketing...

FDA approves anti-clotting drug Savaysa

Drug approved to treat atrial fibrillation, deep vein thrombosis, and pulmonary embolism The U.S. Food and Drug Administration today approved the anti-clotting drug Savaysa (edoxaban tablets) to...

ABBVIE ISSUES STRONG OUTLOOK FOR 2015

- EXPECTS ADJUSTED EARNINGS PER SHARE OF $4.25 TO $4.45 (GAAP EPS OF $3.99 TO $4.19); GUIDANCE TO BE FURTHER REFINED AS HCV LAUNCH PROGRESSES - GUIDANCE MIDPOINT REFLECTS ADJUSTED EPS GROWTH OF MORE...

Amgen To Present At The 33rd Annual J.P. Morgan Healthcare Conference

THOUSAND OAKS, Calif., Jan.

ATHENA data publication reinforces new interim guidance from medical societies on use of HPV as first-line test in cervical cancer screening

SGO, ASCCP leverage newly published end-of-study data to support option of HPV primary screening for women 25 and older

INDIANAPOLIS

Actavis Confirms Appeals Court Grants Expedited Appeal of Ruling Requiring Continued Distribution of NAMENDA® IR

DUBLIN, Jan. 6, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the U.S. Court of Appeals for the Second Circuit granted the Company's motion to expedite its appeal of a lower...

GW Pharmaceuticals and Otsuka Announce Results in First of Three Sativex(R) Phase 3 Cancer Pain Trials

- Primary endpoint did not show a statistically significant difference for Sativex compared with placebo in reducing pain - Conference call and webcast with GW management scheduled at 8:00 a.m. EST,...

Lilly Provides Update on Strategy and Announces 2015 Financial Guidance

- The company describes refinements to its innovation-based strategy, including greater focus on core therapeutic areas and key geographies.

Director General of EFPIA: "Pan-European HTA necessary"

London, January 5 2015: Richard Bergström, Director General, EFPIA argued passionately in favour of the homogenisation of European HTA bodies and regulation, during a recent interview with Paul...

23andMe and Genentech to Analyze Genomic Data for Parkinson's Disease

New program will support the identification of novel drug targets to treat Parkinson's disease

MOUNTAIN VIEW, Calif.,